PKI News and Press, PerkinElmer Inc. From 10/17/22

PerkinElmer ( NYSE: PKI ) expects its Q3 organic revenue growth, non-COVID organic revenue growth and adjusted earnings per share to exceed its prior guidance. In its Q2 earnings release , the company guided for Q3 revenue of ~$1.02-1.03B and adj. EPS of $1.40-1.45. It...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it will release its full third quarter 2022 financial results on November 8, 2022. Management will host a webcast the same day at 8:00 a.m. ET to discuss these results. ...

Summary West Pharmaceutical Services is a quality firm that is doing well right now. But this doesn't make the firm an attractive prospect, even if we assume that management's forecast for 2022 is accurate. Shares need to get cheaper if the business is to make for a compelling...

Cellaca ® PLX Image Cytometer redefines workflows, addresses multiple Critical Quality Attributes PerkinElmer, Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca ® PLX Image Cytometry System, a ...

PerkinElmer's ( NYSE: PKI ) Oxford Immunotec said that the U.S. Food and Drug Administration (FDA) approved the use of T-Cell Select reagent kit for automation of its T-SPOT.TB test workflow. The T-Cell Select reagent kit allows for a more automated workflow, aime...

T-Cell Select reagent kit simplifies the T-SPOT.TB test laboratory workflow through automation expanding access to the most sensitive latent TB test on the market PerkinElmer’s (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) ha...

PerkinElmer, Inc. (PKI) Baird’s 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson - Baird Presentation Tom Peterson Thanks, everyone. ...

Summary PerkinElmer has sold a substantial business in recent times, in order to fully focus on life science and diagnostic activities. The deal looks a bit cheap but is likely okay in the long run. Valuations have come down, despite a resilient performance, creating a compell...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market woke up on the wrong side of the bed yesterday, driving the S&P 500, Dow and NASDAQ down 2.1%, 1.9% and 2.6%, respectively. While stocks chopped around today, the volatility is par for the course right ...

Stifel has downgraded PerkinElmer ( NYSE: PKI ) from buy to hold following the recent announcement that Jamey Mock is leaving as the company's CFO . The firm also reduced its price target to $170 from $190 (~13% upside based on Wednesday's close). Analyst Daniel Ar...